Buy SAXENDA® 6mg/ml – 3mg Pen Online

Saxenda® is a glucagon-like peptide-1 (GLP-1) receptor agonist used for weight management in obese or overweight patients with related comorbidities. It acts by reducing appetite, promoting weight loss, and maintaining lower calorie intake. Saxenda® is primarily indicated as an adjunct to diet and physical activity for patients with an initial BMI of 30 kg/m² (obese) or 27 kg/m² (overweight) in the presence of weight-related conditions such as hypertension or type 2 diabetes. It is available as a 6 mg/mL solution in pre-filled syringes and is injected subcutaneously.

Saxenda® Indications for Use

Saxenda® is recommended for:

• Adult patients with a BMI of 30 kg/m² (obese) or 27 kg/m² (overweight) with at least one weight-related condition (e.g., dyslipidemia, hypertension, type 2 diabetes).
• Pediatric patients aged 12 and older with a body weight above 60 kg and an initial BMI corresponding to 30 kg/m² for adults.

Limitations:

• Not to be used with other GLP-1 receptor agonists or liraglutide-containing products.
• The safety and efficacy in pediatric patients with type 2 diabetes are not established​.

Saxenda® Dosage Information

Saxenda® is administered via subcutaneous injection. Key dosing details include:

• Initial dose: Start with 0.6 mg daily for one week.
• Dose escalation: Increase weekly until the maintenance dose of 3 mg daily is reached.
  • Week 1: 0.6 mg
  • Week 2: 1.2 mg
  • Week 3: 1.8 mg
  • Week 4: 2.4 mg
  • Week 5 onward: 3 mg​.
• Administration sites: Injections can be given in the abdomen, thigh, or upper arm. Timing is flexible and does not depend on meals​.

If a dose is missed, Saxenda® should be resumed with the next scheduled dose. If more than 3 days have passed since the last dose, restart at 0.6 mg to minimize gastrointestinal side effects​.

Saxenda® Side Effects and Precautions

Common side effects affecting more than 5% of patients include:

• Nausea, diarrhea, constipation, vomiting, and injection site reactions.
• Hypoglycemia, particularly in patients with type 2 diabetes using insulin or sulfonylureas​.

Serious side effects:

• Thyroid C-cell tumors: Animal studies showed an increased risk, though it is uncertain whether this applies to humans. Saxenda® is contraindicated for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)​.
• Acute pancreatitis: If symptoms such as severe abdominal pain occur, Saxenda® should be discontinued​.
• Gallbladder disease: Reports of cholelithiasis (gallstones) and cholecystitis were observed, especially in patients with rapid weight loss​.
• Suicidal thoughts: In both adult and pediatric trials, some patients reported suicidal ideation. Close monitoring is recommended, and Saxenda® should be discontinued if such symptoms develop​.

Saxenda® Clinical Studies and Outcomes

Adult Clinical Trials:

• In trials involving 3,384 adults, 9.8% of patients discontinued due to adverse effects. Common reasons for discontinuation included nausea, vomiting, and diarrhea.
• Saxenda® showed significant weight reduction in adults, with patients experiencing 39.3% nausea, 20.9% diarrhea, and 15.7% vomiting​.

Pediatric Clinical Trials:

• A trial in 125 pediatric patients aged 12 to 17 showed that 42.4% of patients reported nausea, and 34.4% reported vomiting. 1 pediatric patient committed suicide, although the relation to Saxenda® is unconfirmed​​.

Saxenda® Drug Interactions

Saxenda® may affect the absorption of oral medications due to its delaying effect on gastric emptying. While interactions with common medications, including oral contraceptives, are minimal, monitoring is advised​.

Saxenda® Administration Instructions

• Proper training in injection technique is crucial to minimize the risk of improper administration. Patients should visually inspect Saxenda® before use, ensuring the solution is clear and colorless​.
• Rotate injection sites within the abdomen, thigh, or upper arm to reduce the risk of cutaneous amyloidosis (localized thickening)​.

Saxenda® Contraindications

Saxenda® is contraindicated for:

• Patients with a personal or family history of MTC or MEN 2​.
• Patients with hypersensitivity to liraglutide or other ingredients​.
• Pregnant women: Saxenda® should not be used during pregnancy, as weight loss offers no benefit and poses risks​.